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Abstract
BACKGROUND AND OBJECTIVES: Postvaccination syncope can cause injury. Drinking 
water prephlebotomy increases peripheral vascular tone, decreasing risk of blood-donation 
presyncope and syncope. This study evaluated whether drinking water prevaccination reduces 
postvaccination presyncope, a potential syncope precursor.
METHODS: We conducted a randomized trial of subjects aged 11 to 21 years receiving ≥1 
intramuscular vaccine in primary care clinics. Intervention subjects were encouraged to drink 500 
mL of water, with vaccination recommended 10 to 60 minutes later. Control subjects received 
usual care. Presyncope symptoms were assessed with a 12-item survey during the 20-minutes 
postvaccination. Symptoms were classified with a primary cutoff sensitive for presyncope, and a 
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secondary, more restrictive cutoff requiring greater symptoms. Results were adjusted for clustering 
by recruitment center.
RESULTS: There were 906 subjects randomly assigned to the control group and 901 subjects 
randomly assigned to the intervention group. None had syncope. Presyncope occurred in 36.2% of 
subjects by using the primary definition, and in 8.0% of subjects by using the restrictive definition. 
There were no significant differences in presyncope by intervention group for the primary (1-sided 
test, P = .24) or restrictive outcome (1-sided test, P = .17). Among intervention subjects vaccinated 
within 10 to 60 minutes after drinking all 500 mL of water (n = 519), no reduction in presyncope 
was observed for the primary or restrictive outcome (1-sided tests, P = .13, P = .17). In 
multivariable regression analysis, presyncope was associated with younger age, history of passing 
out or nearly passing out after a shot or blood draw, prevaccination anxiety, receiving >1 injected 
vaccine, and greater postvaccination pain.
CONCLUSIONS: Drinking water before vaccination did not prevent postvaccination presyncope. 
Predictors of postvaccination presyncope suggest opportunities for presyncope and syncope 
prevention interventions.
Although uncommon, syncope can occur after vaccination and lead to serious injury.1,2 The 
National Academy of Medicine (formerly the Institute of Medicine) has concluded that 
evidence “convincingly supports a causal relationship between the injection of a vaccine and 
syncope,”3 likely because of a vasovagal reaction. In adolescents and young adults, 
postvaccination syncope occurs approximately once per 1000 doses administered, typically 
within 15 minutes after vaccination.1,3,4 Postvaccination presyncope symptoms (eg, 
lightheadedness, dizziness) are more common than syncope.5 Presyncope may precede 
syncope but does not always lead to syncope.6
To minimize risk of injury associated with postvaccination syncope, the Advisory 
Committee on Immunization Practices recommends that adolescents and adults be seated or 
lying down during vaccination and that providers consider observation for 15 minutes after 
vaccination.7 The effectiveness of this practice is not known. There are no evidence based 
recommendations for primary prevention of postvaccination syncope.
One potential strategy to prevent postvaccination syncope is oral hydration before 
vaccination. Drinking water shortly before blood donation induces an increase in peripheral 
vascular tone mediated by sympathetic nervous system activation.8–10 Although blood 
donation is different in many respects from vaccination (eg, blood loss, needle size, 
duration), prevaccination hydration could possibly be an effective syncope prevention 
measure through mechanisms independent of intravascular volume expansion.11
Conducting a trial to assess prevaccination hydration on the outcome of postvaccination 
syncope would require a large number of subjects. Presyncope is more common, both 
syncope and presyncope are vasovagally mediated, and the risk of both might be reduced by 
prevaccination hydration. Therefore, for this study, we chose presyncope as a surrogate 
measure for syncope. The primary objectives of this study were to determine if drinking 
water before intramuscular (IM) vaccination reduces symptoms of presyncope in adolescents 
and young adults and to assess acceptability of this intervention. Secondary objectives 
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included describing rates of presyncope and syncope, and assessing the association of 
selected factors with predicting postvaccination presyncope or syncope.
METHODS
Study design
We conducted a multisite, randomized, open-label study of oral water hydration before 
vaccination for adolescents and young adults receiving at least 1 IM vaccine. The study was 
approved by the institutional review boards at the Duke University School of Medicine and 
Boston University Medical Center. The Centers for Disease Control and Prevention (CDC) 
relied on the Duke University School of Medicine Institutional Review Board.
Patient Population
Subjects aged 11 to 21 years were enrolled from typical, busy, primary care clinics affiliated 
with the Duke University School of Medicine and the Primary Care and Adolescent 
practices at Boston Medical Center. Eligible subjects were those receiving at least 1 IM 
vaccine as part of their usual care, willing to attempt to drink up to 500 mL of water, not 
taking daily injectable medications, and not having received an experimental vaccine or 
experimental medication within the previous 2 weeks. Written consent was obtained from 
subjects ≥18 years old. For younger subjects, written consent was obtained from a guardian 
with assent from the subject.
Study Procedures
After enrollment, subjects were randomly assigned 1:1 with a computer-generated algorithm 
to routine care (control group) or to prevaccination hydration (intervention group). 
Demographic information was collected from subjects. A standardized brief medical history 
was taken, including past history of presyncope and syncope. We collected information 
about sleep the previous night, foods and beverages consumed the day of enrollment, and 
hunger and thirst at the time of enrollment. Vital signs, weight, and height were recorded; 
BMI was calculated and categorized by using the age- and sex-specific CDC growth chart 
into normal weight (<85th percentile), overweight (85th–95th percentile), and obese (≥95th 
percentile).12 Subjects completed the Patient- Reported Outcomes Measurement Information 
System anxiety short form instrument for adolescents (11–17 years) or adults (≥18 years) to 
categorize their degree of anxiety before vaccination.13,14 After vaccination, subjects 
verbally reported their degree of pain by using a visual analog scale from 0 to 5 (Faces Pain 
Scale–Revised),15 and symptoms of presyncope by using a standardized instrument, 
described below. Subjects were observed for 20 minutes for signs of presyncope, syncope, or 
any spontaneous reports of these symptoms. Acceptability of the intervention was based on 
the degree to which subjects drank the water and an open ended question about whether they 
liked receiving the water.
Intervention
Subjects randomly assigned to the hydration group were provided with a 500 mL bottle of 
commercially available water and were asked to drink as much of the water as they could 
without feeling uncomfortable within a 15-minute period. The volume of water remaining in 
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the bottle was measured and recorded. The amount consumed was calculated to be 500 mL 
less the amount of water remaining in the bottle. Vaccinations were recommended to be 
administered by members of the practice during the 10 to 60 minutes after hydration.
Case definitions and outcomes
There is no standard research case definition of presyncope. In consultation with the CDC’s 
Clinical Immunization Safety Assessment Project (http://www.cdc.gov/ vaccinesafety/
ensuringsafety/ monitoring/cisa/), we developed primary and secondary definitions for 
presyncope. The previously validated 11-item Blood Donation Reaction Inventory16,17 
provided the basis for capturing presyncope. The Blood Donation Reaction Inventory asks 
about symptoms of faintness, dizziness, weakness, facial flush, visual disturbance, difficulty 
hearing, lightheadedness, rapid or pounding heartbeat, sweating, rapid or difficult breathing, 
and nausea. One item was added: feeling cold and sweaty or “clammy.” Participants were 
observed for 20 minutes after immunization and information about subjects’ symptoms were 
collected by using the modified questionnaire administered verbally. Subjects rated each of 
the 12 symptoms on a 5-point Likert scale ranging from 1 (“not at all”) to 5 (“extremely”). 
For the primary outcome, we operationalized presyncope as an answer of 2 (“a little bit”) or 
more for any of the 12 items. For the secondary “restrictive” definition, we operationalized 
presyncope as an answer of 3 (“somewhat”) or more for any of the 12 items. We planned a 
priori to exclude subjects who had signs or symptoms of presyncope at baseline or who 
developed presyncope because of another cause. We also planned a priori to classify subjects 
who developed postvaccination syncope after presyncope based on either measure as only 
having syncope to avoid double counting events. During the 20-minute observation period, 
research staff recorded any spontaneous episode of syncope or observed signs or 
spontaneous subject reports of symptoms of presyncope.
Evaluation of Effectiveness
We evaluated the effectiveness of prevaccination oral hydration by comparing the rates of 
the primary and of the restrictive outcomes in the control group to the intervention group, 
regardless of how much subjects drank. We also conducted sensitivity analyses including 
only those subjects in the treatment group who consumed the full 500 mL of water and were 
vaccinated 10 to 60 minutes later because this was the group most likely to have a treatment 
effect.
All analyses were conducted with Stata 14 (StataCorp, College Station, TX). χ2 tests were 
used for categorical data and the Wilcoxon rank test was used to compare median values for 
continuous variables. We also evaluated outcomes by recruitment center (Duke and Boston) 
to explore center differences. To address any baseline differences by center and possible 
correlation of data, selected analyses of treatment effect as indicated in the results section 
were adjusted for clustering by recruitment center.18 To calculate the adjusted likelihood of 
presyncope among the control and intervention group, binary generalized linear modeling 
using the logit function adjusting for clustering by recruitment center was used.18 We 
considered P < .05 to be statistically significant.
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Additional Analyses
We conducted additional post hoc analyses to evaluate the relationship between factors 
previously associated with presyncope and syncope in vaccine studies or in studies of blood 
donation for all subjects overall and stratified by intervention group versus control group, 
including the following: age, sex, BMI, level of prevaccination anxiety, the overall number 
of injected vaccines received, pain, and receipt of human papillomavirus vaccine (HPV).
1–6,19–21
 We also included other variables possibly predictive of presyncope, including race 
and/or ethnicity, self-report of passing out (fainting) or nearly passing out after a shot or 
blood draw, and hunger or thirst at the time of enrollment in the study.19,22 We first 
conducted bivariate analyses and then used multivariable logistic regression using those 
variables significantly associated in the bivariate analyses (P < .05) with presyncope or 
syncope with either the primary or restrictive definition. In these regression models, we also 
included intervention group; recruitment center was treated as a fixed effect to adjust for 
clustering.18 We used link tests to rule out specification error and tested for multicollinearity 
among all predictor variables by using variance inflation factors.
Power calculation and statistical analysis
The goal was to enroll 1800 subjects with equal numbers in the intervention and control 
groups. Statistical power was based on the detection of the combined outcome of presyncope 
and syncope during the postvaccination observation period. A priori power calculations were 
based on estimates of the base rate of events expected in the control group and a 1-sided test 
(α = .05). A 1-sided test was justified because prevaccination hydration would likely only 
decrease, not increase, the risk of presyncope or syncope. We estimated the risk of 
presyncope to be 4% based on the rate of dizziness reported in prelicensure trials of the 
quadrivalent HPV vaccine.23 Based on this estimation, the study would have 80% power to 
detect at least a 50% relative risk reduction in the intervention group by using a χ2 test. We 
anticipated that the spontaneous rate might be higher because of actively soliciting a broad 
range of symptoms. If the spontaneous risk were higher, the statistical power to detect a risk 
reduction would also increase. For example, the study would have 80% power if the 
spontaneous risk were 10% to detect a 32% relative risk reduction. All tests based on 1-sided 
P values are noted in the results. Otherwise, 2-sided tests were used.
RESULT
Subjects
From January 2015 through June 2016, 2918 individuals were approached for participation, 
of whom 1820 were randomly assigned to groups. Thirteen subjects were excluded after 
randomization, leading to the analysis of 1807 total subjects, 906 in the control group and 
901 in the intervention group (Fig 1).
There were no significant differences between the intervention and control groups across a 
broad array of subject characteristics unadjusted by recruitment center (Table 1). Most 
subjects received only 1 IM vaccine (control 58.0%, intervention 57.1%; P = .70), 26.8% 
received 2 IM vaccines, and 15.4% received 3 or more IM vaccines, with no significant 
difference between the control and intervention groups (P = .60). The subjects received the 
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following IM vaccines: HPV vaccine (57.4%); quadrivalent meningococcal vaccine (42.5%); 
inactivated influenza vaccine (25.6%); tetanus and diphtheria or tetanus, diphtheria, and 
acellular pertussis vaccine (Tdap) (16.9%); hepatitis A vaccine (11.7%); and hepatitis B 
vaccine (2.4%). Most subjects vaccinated against HPV received the 9-valent vaccine 
(71.3%); the remainder (28.7%) received the 4-valent vaccine. In addition to the IM 
vaccine(s), subcutaneous vaccines included varicella (1.7%), as well as measles, mumps, and 
rubella (0.1%). Few subjects received intranasal influenza vaccine (control 2.2%, 
intervention 1.4%; P = .23). All subjects were sitting during vaccination. Some subjects 
(control 12.9%, intervention 12.6; P = .82) were moved to a different room for 
postvaccination observation. There was no difference (P = .68) in position between the 
groups after vaccination; most subjects (92.4%) were sitting and few were lying down 
(0.9%), standing (6.2%), or walking (0.5%).
Postvaccination pain was similar between the groups (P = .75). Most subjects (57.3%) 
reported no pain, 29.2% reported mild pain (1 out of 5), and 13.5% reported a greater 
amount of pain (2 or more out of 5). Subjects who received >1 injectable vaccine were more 
likely to report pain. Among subjects who received only 1 vaccine, 9.9% reported a pain 
score of 2 or more out of 5 compared with 20.5% of subjects who received 2 or more 
vaccines (P < .001). Prevaccination anxiety was also associated with pain. Overall, 13.2% of 
subjects with less than mild anxiety reported a pain score of 2 or more compared with 16.8% 
of subjects with greater anxiety (P = .04).
All subjects in the intervention group drank some water; most (64.9%) drank all 500 mL of 
water, and 78.3% drank more than half. Only 4.8% reported not liking getting a drink, most 
typically because they either did not like to drink water or were not thirsty. The median time 
from finishing the water to vaccination was 13 minutes (interquartile range [IQR]: 5–19 
minutes). There were 272 subjects (30.2% in the intervention group) vaccinated <10 minutes 
and 3 subjects >60 minutes after the recorded end of hydration. Most (95.4%) of these 
subjects were recruited at the Boston Medical Center. Those with <10 minute wait time had 
a median water consumption time averaging 10 minutes (IQR: 7–23 minutes) followed by a 
wait period of 2 minutes (IQR: 0–5 minutes) before vaccinations were administered.
Outcome Events
There were no episodes of syncope and 20 episodes of observed presyncope. These episodes 
of presyncope also met the criteria for the primary and restrictive presyncope outcome 
definitions. Subjects recruited at Duke clinics were more likely to have the primary outcome 
(report of “a little bit or more” of any presyncope symptom) than those recruited at Boston 
Medical Center clinics (42.5% vs 26.7%; P < .001). However, there was no difference by 
recruitment center for the restrictive outcome (report of “some or more” presyncope 
symptom) (Duke: 8.7% vs Boston Medical Center: 7.0%; P = .19).
After adjusting for clustering by recruitment center, 36.2% of subjects reported presyncope 
according to the primary study definition and 8.0% of subjects reported presyncope 
according to the restrictive outcome definition. The most commonly reported symptom was 
“feeling weak.” For 18.7% of the subjects classified with the primary outcome and 20.5% 
classified with the restrictive outcome, the only reason was a report of weakness.
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Effect on Postvaccination Presyncope
After adjusting for clustering by recruitment center, the primary outcome occurred in 37.1% 
(95% confidence interval [CI]: 34.0%–40.2%) of the control group and in 35.3% (95% CI: 
32.2%– %) of the intervention group (1-sided test, P = .24) for any volume of water 
consumed. The restrictive outcome occurred in 8.6% (95% CI: 6.8%–10.4%) of the control 
group and in 7.3% (95% CI: 5.6%–9.1%) of the intervention group (1-sided test, P = .17).
No statistically significant differences between control and intervention groups for either 
outcome measure were found in the sensitivity analyses. When restricting the intervention 
group to those who drank 500 mL of water and were vaccinated within 10 to 60 minutes (n = 
519), the primary outcome occurred in 39.2% of the control group and 35.9% of the 
intervention group (1-sided P = .13) and the restrictive outcome occurred in 8.9% of the 
control group and 7.5% of the intervention group (1 sided P = .17). Overall outcomes were 
similar in the control and intervention groups within the recruitment centers (Duke [primary: 
control 44.2%, intervention 40.7%, 1-sided P = .12; restrictive: control 9.6%, intervention 
7.8%, 1-sided P = .15] and Boston Medical Center [primary: control 26.3%, intervention 
27.1%, 1-sided P = .41; restrictive: control 7.2%, intervention 6.7%, 1-sided P = .40]).
Predictors of Postvaccination Presyncope
Table 2 lists the associations between the selected subject characteristics and the primary 
and restrictive outcome, regardless of intervention group, adjusted only by clustering by 
recruitment center. Younger age, female sex, report of passing out (fainting) after a shot or 
blood draw in the past 5 years, greater prevaccination anxiety, receipt of >1 injectable 
vaccine, receipt of HPV vaccine, and greater pain intensity were associated with the primary 
outcome. Female sex and receipt of HPV vaccine were not associated with the restrictive 
outcome. We created an indicator variable for being either very hungry or thirsty. Being 
either very hungry or thirsty at the time of enrollment was associated with the restrictive but 
not primary outcome.
Table 3 summarizes the results of the multivariable logistic regression analyses to predict 
presyncope Younger age, report of passing out after a shot or blood draw, greater 
prevaccination anxiety, receiving >1 injectable vaccine, and greater pain after vaccination 
were associated with postvaccination presyncope by using both the primary and restrictive 
outcomes. In the model, female sex, hunger or thirst, and receipt of HPV vaccine were not 
associated with presyncope based on either the primary or restrictive outcome definitions. 
Assignment to prevaccination hydration also was not associated with presyncope with either 
the primary or restrictive definition.
DISCUSSION
In this randomized trial, contrary to our hypothesis, we found that drinking up to 500 mL of 
water before vaccination did not decrease postvaccination presyncope in adolescents and 
young adults. The authors of a recent meta-analysis found a decreased relative risk (0.79) for 
vasovagal reactions in the context of blood donation after drinking water before the 
phlebotomy compared to usual care.10 Although it was biologically plausible to believe that 
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drinking water before vaccination would decrease presyncope after vaccination, we did not 
observe this effect. These findings highlight the need to conduct randomized clinical trials to 
evaluate postvaccination presyncope and syncope prevention strategies rather than applying 
lessons from the blood banking literature without study.
Authors of blood donation literature have identified risk factors for donation-associated 
presyncope and syncope1,2,6,19–21; however, authors of immunization literature have 
reported little evidence identifying risk factors for postvaccination presyncope and syncope. 
Our post hoc analyses identified predictors of postvaccination presyncope, including 
younger age, report of passing out (fainting) or nearly passing out after a shot or blood draw, 
prevaccination anxiety, receipt of 2 or more injectable vaccine compared to only 1, and a 
greater degree of postvaccination pain. These predictors could help clinicians identify 
patients at a higher risk for postvaccination presyncope or syncope and serve as targets for 
future prevention interventions. For example, interventions to reduce anxiety before 
vaccination or to address pain after vaccination could be evaluated to determine if these are 
effective methods of preventing postvaccination presyncope.
Although our main interest is to prevent syncope and associated injury, these outcomes are 
uncommon. We therefore used presyncope as the primary study outcome because of its 
higher frequency, association with syncope, and the potential for it to be modified by oral 
hydration. A significant challenge to the tudy was classifying presyncope. Individuals with 
presyncope might not spontaneously report symptoms and observers might not recognize 
signs. We therefore further elicited symptoms with a slightly modified validated instrument. 
Although administering the instrument before and after vaccination might have helped 
determine change in symptoms, we did not administer the instrument before vaccination 
because we thought that doing so might increase subject concerns about vaccination and bias 
results. Because the optimal cutoff value for classifying presyncope using the instrument is 
not known, we used 2 different thresholds: a primary one that we believed would trade off 
improving sensitivity against potentially lower specificity, and a restrictive one that could 
improve specificity but risk misclassifying a true case.
Another important factor is that nearly 30% of the intervention group had <10 minutes 
between the completion of hydration and vaccination. This study was conducted in busy 
clinical practices. Even with added research support, it was challenging to ensure the time 
for water consumption followed by adequate wait time to allow for any reflex increase in 
peripheral vascular tone. Sometimes it was uncertain when individuals had completed 
drinking because they were allowed to drink in the waiting and examining rooms. 
Optimizing clinic flow and prioritizing patient care and treatment, including vaccinations, in 
these busy primary care clinics was sometimes chosen over strict adherence to timing of the 
water consumption protocol, including the wait periods.
CONCLUSION
We did not find that drinking water before vaccination and Regional Pediatrics. to be 
effective in reducing postvaccination presyncope in adolescents and young adults. However, 
the study did identify factors associated with postvaccination presyncope that could be 
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targeted in future research to develop feasible and effective postvaccination presyncope and 
syncope prevention strategies.
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WHAT’S KNOWN ON THIS SUBJECT:
Postvaccination syncope can cause injury. Drinking water before venipuncture for blood 
donation decreases syncope risk by increasing vascular tone.
Kemper et al. Page 11
Pediatrics. Author manuscript; available in PMC 2018 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
WHAT THIS STUDY ADDS:
In a typical practice setting, drinking water before vaccination had no overall impact on 
postvaccination presyncope, a potential precursor of syncope.
To cite: Kemper AR, Barnett ED, Walter EB, et al. Drinking Water to Prevent 
Postvaccination Presyncope in Adolescents: A Randomized Trial. Pediatrics. 2017; 
140(5):e20170508
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FIGURE 1. 
Flow diagram of enrollment, allocation (control group or the intervention group receiving 
prevaccination oral water hydration), follow-up, and analysis. Protocol violations are when 
subjects were not observed for 20 minutes after vaccination.
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TABLE 1
Baseline Characteristics for the Subjects Randomly Assigned to the Control Group or Intervention 
(Prevaccination Oral Water Hydration) Group
Control (n = 906) Intervention (n = 901) P
Age, y 15 (12–17)a 15 (12–17)a .62
Sex (% female) 49.6 53.0 .15
Race, % .80
 White 44.7 44.4 —
 African American 43.9 42.4 —
 Asian American 2.8 2.9 —
 American Indian 0.1 0.2 —
 Native Hawaiian/Pacific Islander 0.3 0.1 —
 Other 5.2 6.4 —
 Missing 3.0 3.6 —
Ethnicity, % .31
 Hispanic 9.4 11.5 —
 Non-Hispanic 89.4 87.1 —
 Missing 1.2 1.3 —
BMI, % .58
 Normal 60.0 60.1 —
 Overweight 21.9 20.3 —
 Obese 18.1 19.6 —
Insurance status, % .79
 Only public 38.4 38.5 —
 Any private 60.5 60.4 —
 None 1.1 1.0 —
Ever nearly passed out or passed out in the
 past 5 y, % —
 In the heat 14.5 15.5 .55
 After a shot 2.1 2.1 .99
 After blood draw 4.8 4.8 .97
 After or during exercise 19.2 17.1 .24
Tiredness at the time of enrollment, % .43
 Not at all or a little bit 93.8 94.7 —
 Very 6.2 5.3 —
Hunger at the time of enrollment, % .18
 Not at all or a little bit 87.3 85.1 —
 Very 12.7 14.9 —
Thirst at the time of enrollment, % .12
 Not at all or a little bit 88.0 90.3 —
 Very 12.0 9.7 —
Hours of sleep the previous night 8 (7–9)a 8 (7–9)a .94
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Control (n = 906) Intervention (n = 901) P
Hours since last food 3 (2–5)a 3 (2–5)a .57
Hours since last drink 2 (1–4)a 3 (1–5)a .09
Prevaccination anxiety, % .32
 None or slight 79.3 77.0 —
 Mild 12.1 12.5 —
 Moderate 7.7 10.0 —
 Severe 0.9 0.5 —
—
not applicable.
a
Median (IQR).
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TABLE 2
Association of Subject Characteristics With the Primary and Restrictive Outcomes Regardless of Intervention 
Group Adjusted for Clustering by Recruitment Center
Primary Restrictive
Outcomea Outcome
Age, y, %
 <15 44.2 11.1
 ≥15 29.0 5.4
P < .001 P < .001
Sex, %
 Male 33.2 7.1
 Female 39.0 8.8
P = .01 P = .11
Race and ethnicity, %
 Non-Hispanic white 36.3 7.5
 Non-Hispanic African American 37.0 8.5
 Hispanic 35.2 8.5
 Other 35.3 6.8
P = .80 P = .94
BMI, %
 Normal 37.8 7.9
 Overweight or obese 34.3 8.2
P = .14 P = .21
Passed out or nearly passed out from shot or blood draw in
 the past 5 y, %
 No 35.4 7.5
 Yes 47.8 15.1
P = .009 P = .02
Hunger or thirst at the time of enrollment, %
 Not at all or a little bit 35.3 7.2
 Very 39.2 10.9
P = .13 P = .02
Tired at the time of enrollment, %
 Not at all or a little bit 35.6 7.8
 Very 40.1 13.9
P = .36 P = .07
Prevaccination anxiety, %
 None or slight 33.9 6.3
 Mild, moderate, or severe 40.8 11.5
P = .004 P < .001
No. of injectable vaccines,b %
 1 30.6 5.2
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Primary Restrictive
Outcomea Outcome
 >1 43.7 11.8
P < .001 P < .001
Receipt of HPV vaccine, %
 No 33.8 7.3
 Yes 38.3 8.5
P = .02 P = .11
Pain intensity after vaccination, %
 0–1 31.9 5.1
 2–5 62.0 26.1
P < .001 P < .001
a
The primary outcome is “a little bit” or more in response to any of the 12 items on the presyncope instrument. The restrictive outcome is 
“somewhat” or more in response to any of the 12 items on the presyncope instrument.
b
Including intramuscularly and subcutaneously administered vaccines.
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TABLE 3
Multivariable Logistic Regression Analyses to Predict the Risk of Postvaccination Presyncope Defined by the 
Primary and Restrictive Outcomes
Primary Outcomea Restrictive
aOR (95% CI) Outcomea aOR
(95% CI)
Age, y
 <15 2.27 (1.79–2.88) 2.84 (1.83–4.39)
 ≥15 Reference Reference
Sex
 Male Reference Reference
 Female 1.20 (0.97–1.48) 1.03 (0.71–1.51)
Passed out or nearly passed out from shot or blood draw
 in the past 5 y
 No Reference Reference
 Yes 1.91 (1.27–2.87) 2.70 (1.48–4.91)
Hunger or thirst
 Not at all or a little bit Reference Reference
 Very 1.15 (0.90–1.47) 1.46 (0.97–2.19)
Prevaccination anxiety
 None or slight Reference Reference
 Mild, moderate, or severe 1.86 (1.45–2.38) 2.77 (1.82–4.20)
No. of injectable vaccines
 1 Reference Reference
 >1 1.53 (1.24–1.89) 1.95 (1.33–2.86)
Receipt of HPV vaccine
 No Reference Reference
 Yes 1.03 (0.83–1.28) 1.00 (0.68–1.48)
Pain intensity
 0–1 Reference Reference
 2–5 2.96 (2.21–3.98) 4.96 (3.34–7.36)
Group
 Control Reference Reference
 Intervention 0.92 (0.75–1.13) 0.84 (0.58–1.21)
The outcomes were adjusted for each listed variable and enrollment center. aOR, adjusted odds ratio.
a
The primary outcome is “a little bit” or more in response to any of the 12 items on the presyncope instrument. The restrictive outcome is 
“somewhat” or more in response to any of the 12 items on the presyncope instrument.
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